BNET Industries
Market Cap:$103.2B
Last Fiscal Year Sales:$32.9B
- Public
- FR
Dow Jones Description
Sanofi-Aventis sees the future - where disease is in the past. Formed by a 2004 merger and headquartered in Paris, France, Sanofi-Aventis (NYSE: SNY (ADR) Euronext Paris: SAN) is the third-largest pharmaceutical maker in the world. The company researches, develops, manufactures, and markets prescription drugs. Its products include Allegra, Aprovel, Eloxatin, Lovenox, Nasacort, Plavix, Taxotere, and Tritace, among others. It has over 100 compounds in development, about 40 of which are in Phase II or III clinical trials. The company has annual revenue of about A28.5 billion and employs about 100,000 people. In March 2006 the company acquired almost 25% of Zentiva NV for approximately A430 million. In 2005 the company sold its interests in Wacker-Chemie.
Number of Employees 97,181
Peer Companies
NAICS Code Drugs and Druggists' Sundries Merchant Wholesalers: 424210
Recent Events
-
800,000 swine flu doses recalled [The Pittsburgh Tribune-Review]
-
Warner Chilcott Affirms Global Marketing and Collaboration Agreement With Sanofi-Aventis
-
Common heart rhythm problem on the rise in the U.S.
-
Sanofi-Aventis and Alopexx sign collaboration agreement
-
Sanofi-Aventis in research pact with CalTech
-
Generex enters insulin supply deal for Oral-lyn
-
86. Sanofi
-
Sanofi-Aventis SNY Announces Agreement with Intelliject for Novel Epinephrine Auto Injector
-
Early and Often: A Drug Investor's Dream
-
Drugmakers' Differences: Analyst's Toolkit
-
Deutsche Bank Initiates Coverage on Sanofi-Aventis SNY with a Buy
-
Big Pharma Willing to Pay for Biotech Innovation
-
Sanofi-Aventis names Spek global operations head 37 mins ago
-
Sanofi-Aventis Q3 Profit Rises; Lifts FY09 Adj. EPS Growth View; To Buy Laboratoire Oenobiol -...
-
UPDATE 3-Sanofi lifts forecast on swine flu vaccine
-
Sanofi-Aventis and Micromet to Develop New Tumour Antibody
-
Dyax Corp. Q3 2009 Earnings Call Transcript
-
Sanofi-Aventis's New JV Will Provide Entry into Chinas OTC Market
-
Mexico pushing for homegrown swine flu vaccine
News & Analysis
Filter by
sanofi and sanofi-aventis - All News and Analysis
Sanofi-Aventis HQ Sells for $230 Million
BNET
- 2008-12-11
Sanofi-Aventis leases its North American headquarters in Bridgewater, N.J. Renting is fine for some, but a recent deal indicates that despite the declining real estate market, Sanofi may have been better off buying its 670,000-foot complex. The Sanofi building, owned by SL Green Realty Corp. and Gramercy...
Should Sanofi-Aventis Buy Bristol Myers-Squibb?
BNET
- 2008-10-27
Bristol-Myers Squibb CEO James Cornelius said in a recent earnings call that due to its healthy cash position it may be on the prowl for biotech acquisitions. That's ironic because it is looking more like BMS itself could be the company to be acquired, possibly by Sanofi-Aventis. ...
Sanofi fighting generic drugs tooth and nail in US courts
- 2006-08-09
PARIS AFP — The French pharmaceuticals group Sanofi-Aventis is turning to vigorous legal action to protect its best-selling drugs in the United States from cheaper generic competition. "We are sure of our patents," a spokesman for Sanofi-Aventis, the world's third largest drug group, said Wednesday. Sanofi announced it...
Sanofi-Aventis posts profit gain; share price tumbles on pipeline news
- 2005-08-31
PARIS AFP — Pharmaceutical group Sanofi-Aventis reported a 26 percent rise in second-quarter net profit from a year ago but its share price fell sharply on a mixed picture for new product prospects. The group posted second-quarter net profit of 1.553 billion euros (1.9 billion dollars), beating analysts' estimates...
- 1
| Volume | 1,461,619 |
| Shares Outstanding | 2.6B |
| Market Cap | 103.2B |
| Year High | 40.28 |
| Year Low | 24.59 |
| Earnings Per Share | 2.21 |
| P/E Ratio | 17.7421 |
| Dividend | 1.0639 |
| Yield | 2.7133 |
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
Presented by American Express